Priority Review

 
News Articles for Priority Review top ^
BioMarin Submits VIMIZIM™ (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status Canada NewsWire Approval would deliver first treatment for Canadians living with ultra-rare, genetic metabolic disorder TORONTO , Dec.
Sign-up for BioMarin Submits VIMIZIM™ (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status investment picks
2013/10/23
INDIANAPOLIS , Oct.
Sign-up for FDA Grants Lilly's Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer investment picks
2013/12/17
Company Announcement Arzerra(r) receives Priority Review from FDA PDUFA date of April 19, 2014 COPENHAGEN, Denmark, Dec.
Sign-up for GSK and Genmab Receive Priority Review from FDA for Arzerra(r) (ofatumumab) as 1st Line Treatment for Chronic Lymphocytic Leukemia (CLL) investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous (IV) solution formulation of the company's antifungal agent, NOXAFIL ® (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration (FDA). Priority review designation is assigned to applications for drugs that, if approved, would provide significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions.
Sign-up for Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL® (posaconazole) Receives FDA Priority Review investment picks
2014/4/7
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s New Drug Application (NDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
Sign-up for Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection investment picks
2013/12/11
By Noemie Bisserbe PARIS--French drug major Sanofi SA (SAN.FR) and its subsidiary Genzyme said Wednesday that the U.S. Food and Drug Administration would review in priority its new drug application for Gaucher disease medication eliglustat, potentially accelerating its entry in the market by months.
Sign-up for U.S. FDA Grants Priority Review to Genzyme's Cerdelga investment picks
Genzyme , a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application (NDA) for Cerdelga™ (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1.
Sign-up for FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease investment picks
2014/3/20
Eagle Pharmaceuticals, Inc. ("EAGLE") (NASDAQ:EGRX) announced today that the United States Food and Drug Administration has accepted the company’s New Drug Application for Ryanodex® (dantrolene) and granted a priority review classification.
Sign-up for NDA for Eagle Pharmaceuticals’ Orphan Drug Ryanodex® for the Treatment of Malignant Hyperthermia Accepted by FDA, Priority Review Granted investment picks
2014/2/19
http://media.marketwire.com/attachments/201310/67049_medicinescompany.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1090973&ProfileId=051205&sourceType=1 PARSIPPANY, NJ --
Sign-up for FDA Accepts Filing of the Medicines Company's New Drug Application for Intravenous Antibiotic Oritavancin With Priority Review investment picks
2014/4/7
By Michael Calia Gilead Sciences Inc. (GILD) on Monday said the Food and Drug Administration has placed the company's new drug application for a hepatitis C treatment under priority review.
Sign-up for Gilead Hepatitis C Treatment Designated for FDA Priority Review investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Priority Review
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Prior-Year Quarter  |  Next: Private Banking